Early decrease of serum biomarkers of type II collagen degradation (Coll2-1) and joint inflammation (Coll2-1 NO(2) ) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis: a research study part of the Biovisco study.
[en] To measure the evolution of the serum levels of specific Osteoarthritis (OA) biomarker, Coll2-1 and Coll2-1 NO(2) in knee osteoarthritic patients after viscosupplementation (VS). Fifty-one patients with unilateral symptomatic knee were recruited for this prospective open label study. They received three intra-articular injections of 2 ml of hyaluronic acid (Hylan GF-20) and were followed for 3 months. Walking pain was evaluated and serum samples were taken at each visit. Coll2-1 and Coll2-1 NO(2) were measured in the serum using specific immunoassays. Variations over time of each parameter and predictive factor of response were studied. Forty-five patients were analyzed. The serum concentrations of Coll2-1 and Coll2-1 NO(2) were significantly higher in KL III/IV patients compared to KL I/II patients at baseline and decreased systematically over time after VS. Its effect was ever more pronounced in patients with KL III/IV. The serum concentration of Coll2-1 was significantly lower at baseline in responders than in non-responders. This study suggests a rapid slowdown of type II collagen degradation and joint inflammation after VS with Hylan G-20 and gives additional information for the validation of accurate biomarkers for OA. The serum level of Coll2-1 appeared to be a predictive factor for response to treatment.
Disciplines :
Rheumatology
Author, co-author :
Henrotin, Yves ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartilage (U.R.O.C.)
Chevalier, X.
DEBERG, Michelle ; Centre Hospitalier Universitaire de Liège - CHU > Génétique
Balblanc, J. C.
Richette, P.
Mulleman, D.
Maillet, B.
Rannou, F.
Piroth, C.
Mathieu, Philippe ; Université de Liège - ULiège > Département d'aérospatiale et mécanique > Département d'aérospatiale et mécanique
Conrozier, T.
Language :
English
Title :
Early decrease of serum biomarkers of type II collagen degradation (Coll2-1) and joint inflammation (Coll2-1 NO(2) ) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis: a research study part of the Biovisco study.
Publication date :
2013
Journal title :
Journal of Orthopaedic Research
ISSN :
0736-0266
eISSN :
1554-527X
Publisher :
Wiley-Blackwell, Hoboken, United States - New Jersey
Osteoarthritis G., 2000. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 43: 1905-1915 (American College of Rheumatology Subcommittee).
Jordan KM, Arden NK, Doherty M, et al. 2003. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62: 1145-1155.
Zhang W, Moskowitz RW, Nuki G, et al. 2007. OARSI recommendations for the management of hip and knee osteoarthritis, Part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 15: 981-1000.
Zhang W, Moskowitz RW, Nuki G, et al. 2008. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16: 137-162.
Zhang W, Nuki G, Moskowitz RW, et al. 2010. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 18: 476-499.
Waddell DD., 2007. Viscosupplementation with hyaluronans for osteoarthritis of the knee: clinical efficacy and economic implications. Drugs Aging 24: 629-642.
Balazs EA., 2004. Viscosupplementation for treatment of osteoarthritis: from initial discovery to current status and results. Surg Technol Int 12: 278-289.
Bagga H, Burkhardt D, Sambrook P, et al. 2006. Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol 33: 946-950.
Balazs EA., 2003. Analgesic effect of elastoviscous hyaluronan solutions and the treatment of arthritic pain. Cells Tissues Organs 174: 49-62.
Gomis A, Miralles A, Schmidt RF, et al. 2007. Nociceptive nerve activity in an experimental model of knee joint osteoarthritis of the guinea pig: effect of intra-articular hyaluronan application. Pain 130: 126-136.
Goto M, Hanyu T, Yoshio T, et al. 2001. Intra-articular injection of hyaluronate (SI-6601D) improves joint pain and synovial fluid prostaglandin E2 levels in rheumatoid arthritis: a multicenter clinical trial. Clin Exp Rheumatol 19: 377-383.
Waddell DD, Kolomytkin OV, Dunn S, et al. 2007. Hyaluronan suppresses IL-1beta-induced metalloproteinase activity from synovial tissue. Clin Orthop Relat Res 465: 241-248.
Yatabe T, Mochizuki S, Takizawa M, et al. 2009. Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes. Ann Rheum Dis 68: 1051-1058.
Biomarkers Definition Working Group. 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89-95.
Henrotin Y, Addison S, Kraus V, et al. 2007. Type II collagen markers in osteoarthritis: what do they indicate ? Curr Opin Rheumatol 19: 444-450.
Deberg M, Labasse A, Christgau S, et al. 2005. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 13: 258-265.
Deberg MA, Labasse AH, Collette J, et al. 2005. One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cartilage 13: 1059-1065.
Lejeune JP, Serteyn D, Gangl M, et al. 2007. Plasma concentrations of a type II collagen-derived peptide and its nitrated form in growing Ardenner sound horses and in horses suffering from juvenile digital degenerative osteoarthropathy. Vet Res Commun 31: 591-601.
Gangl M, Serteyn D, Lejeune JP, et al. 2007. A type II-collagen derived peptide and its nitrated form as new markers of inflammation and cartilage degradation in equine osteochondral lesions. Res Vet Sci 82: 68-75.
Huebner JL, Williams JM, Deberg M, et al. 2010. Collagen fibril disruption occurs early in primary guinea pig knee osteoarthritis. Osteoarthritis Cartilage 18: 397-405.
Ameye LG, Deberg M, Oliveira M, et al. 2007. The chemical biomarkers C2C, Coll2-1, and Coll2-1NO2 provide complementary information on type II collagen catabolism in healthy and osteoarthritic mice. Arthritis Rheum 56: 3336-3346.
Huebner JL, Kraus VB., 2006. Assessment of the utility of biomarkers of osteoarthritis in the guinea pig. Osteoarthritis Cartilage 14: 923-930.
Deberg M, Dubuc JE, Labasse A, et al. 2008. One-year follow-up of Coll2-1, Coll2-1 NO2 and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement. Ann Rheum Dis 67: 168-174.
Conrozier T, Richette P, Balblanc JC, et al. 2010. Les injections intraarticulaires de HYLANE GF-20 réduisent la dégradation du collagène de type II dans la gonarthrose. La Revue du Rhumatisme 77: A46.
Conrozier T, Balblanc JC, Richette P, et al. 2012. Early effect of hyaluronic acid intra-articular injections on serum and urine biomarkers in patients with knee osteoarthritis: an open-label observational prospective study. J Orthop Res 30: 679-685.
Kellgren JH, Lawrence JS., 1957. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16: 494-502.
Conrozier T, Mathieu P, Schott AM, et al. 2003. Factors predicting long-term efficacy of Hylan GF-20 viscosupplementation in knee osteoarthritis. Joint Bone Spine 70: 128-133.
Karna E, Miltyk W, Surazynski A, et al. 2008. Protective effect of hyaluronic acid on interleukin-1-induced deregulation of beta1-integrin and insulin-like growth factor-I receptor signaling and collagen biosynthesis in cultured human chondrocytes. Mol Cell Biochem 308: 57-64.
Surazynski A, Miltyk W, Czarnomysy R, et al. 2009. Hyaluronic acid abrogates nitric oxide-dependent stimulation of collagen degradation in cultured human chondrocytes. Pharmacol Res 60: 46-49.
Karna E, Miltyk W, Palka JA, et al. 2006. Hyaluronic acid counteracts interleukin-1-induced inhibition of collagen biosynthesis in cultured human chondrocytes. Pharmacol Res 54: 275-281.
Akmal M, Singh A, Anand A, et al. 2005. The effects of hyaluronic acid on articular chondrocytes. J Bone Joint Surg Br 87: 1143-1149.
Julovi SM, Ito H, Nishitani K, et al. 2011. Hyaluronan inhibits matrix metalloproteinase-13 in human arthritic chondrocytes via CD44 and P38. J Orthop Res 29: 258-264.
Peng H, Zhou JL, Liu SQ, et al. 2010. Hyaluronic acid inhibits nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes in vitro. Inflamm Res 59: 519-530.
Grishko V, Xu M, Ho R, et al. 2009. Effects of hyaluronic acid on mitochondrial function and mitochondria-driven apoptosis following oxidative stress in human chondrocytes. J Biol Chem 284: 9132-9139.
Kraus VB, Burnett B, Coindreau J, et al. 2011. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage 19: 515-542.
Ratner M., 2005. FDA pharmacogenomics guidance sends a clear message to industry. Nat Rev Drug Discov 4: 359.
